gallium Ga-68 pentixafor

Gallium Ga-68 pentixafor is a radiopharmaceutical imaging agent composed of a synthetic cyclic pentapeptide analog of stromal cell-derived factor-1 (SDF-1 or CXCL12) radiolabeled with gallium-68 via the macrocyclic chelating agent DOTA (dodecanetetraacetic acid)[5]. The pentixafor moiety binds with high affinity to C-X-C chemokine receptor type 4 (CXCR4), which is overexpressed on various cancer cells and plays a key role in tumor growth, progression, invasiveness, and metastasis[1][5]. The radiotracer was initially developed in 2011 by Dr. Wester and colleagues in Munich, Germany[6]. Upon administration, the pentixafor component targets and binds to CXCR4-expressing cells, allowing visualization of CXCR4 expression status through PET/CT imaging[5]. The radiotracer demonstrates rapid renal clearance with maximum tumor activity at 60 minutes post-injection and shows excellent specificity with strong tumor accumulation and low background activity[6]. It is particularly useful for imaging FDG-not-avid lymphomas including lymphoplasmacytic lymphoma, chronic lymphocytic leukemia, marginal zone lymphoma, and central nervous system lymphoma, as well as for evaluating primary aldosteronism and various hematologic malignancies[1][3].

Brand names

gallium Ga 68 boclatixafortide

Other names

[68Ga] pentixaforgallium-68 pentixaforgallium68 pentixaforgallium 68 pentixafor